NTP-LEFLUNOMIDE TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
11-10-2013
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
LEFLUNOMIDE
から入手可能:
TEVA CANADA LIMITED
ATCコード:
L04AK01
INN（国際名）:
LEFLUNOMIDE
投薬量:
10MG
医薬品形態:
TABLET
構図:
LEFLUNOMIDE 10MG
投与経路:
ORAL
パッケージ内のユニット:
30
処方タイプ:
Prescription
治療領域:
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
製品概要:
Active ingredient group (AIG) number: 0140182001; AHFS:
認証ステータス:
CANCELLED PRE MARKET
承認日:
2015-08-06
製品の特徴
PRODUCT MONOGRAPH
Pr
NTP-LEFLUNOMIDE
(Leflunomide)
10 mg and 20 mg Tablets
Antirheumatic Agent
Teva Canada Ltd.
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No.: 167474
Date of Preparation:
October 11, 2013
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
..........................................................................
3
CONTRAINDICATIONS
...............................................................................................
3
WARNINGS AND PRECAUTIONS
..............................................................................
5
ADVERSE REACTIONS
..............................................................................................
13
DRUG INTERACTIONS
..............................................................................................
17
DOSAGE AND ADMINISTRATION
..........................................................................
21
OVERDOSAGE
............................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 22
STORAGE AND STABILITY
......................................................................................
25
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................... 25
PART II: SCIENTIFIC INFORMATION
...............................................................................
27
PHARMACEUTICAL INFORMATION
......................................................................
27
CLINICAL TRIALS
......................................................................................................
28
DETAILED PHARMACOLOGY
.................................................................................
35
TOXICOLOGY
.......................................................................
完全なドキュメントを読む
